ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
ZIVO Bioscience (OTCQB: ZIVO) announces a second collaborative study with the University of Delaware to explore applications of its proprietary algal-derived ingredients in fighting Low Pathogenicity Avian Influenza (LPAI) virus in poultry. The announcement follows their previous successful study that showed significant reduction in viral shedding and delayed disease transmission in treated birds.
The new study aims to optimize formulations and treatment protocols for real-world poultry production environments. Several global animal health companies have expressed interest in ZIVO's non-antibiotic solutions, following positive results from both avian influenza and coccidiosis studies. The company's approach focuses on developing sustainable, cost-effective alternatives to traditional treatments using their proprietary algal cultures.
ZIVO Bioscience (OTCQB: ZIVO) annuncia un secondo studio collaborativo con l'Università del Delaware per esplorare le applicazioni dei suoi ingredienti derivati dagli alghe nella lotta contro il virus dell'Influenza Aviaria a Bassa Patogenicità (LPAI) nel pollame. L'annuncio segue il loro precedente studio di successo che ha mostrato una significativa riduzione nella diffusione virale e un ritardo nella trasmissione della malattia negli uccelli trattati.
Il nuovo studio mira a ottimizzare le formulazioni e i protocolli di trattamento per ambienti di produzione avicola reali. Diverse aziende globali nel settore della salute animale hanno espresso interesse per le soluzioni non antibiotiche di ZIVO, dopo i risultati positivi degli studi sia sull'influenza aviaria che sulla coccidiosi. L'approccio dell'azienda si concentra sullo sviluppo di alternative sostenibili ed economiche ai trattamenti tradizionali utilizzando le loro culture algali proprietarie.
ZIVO Bioscience (OTCQB: ZIVO) anuncia un segundo estudio colaborativo con la Universidad de Delaware para explorar las aplicaciones de sus ingredientes derivados de algas en la lucha contra el virus de la Influenza Aviaria de Baja Patogenicidad (LPAI) en aves de corral. El anuncio sigue a su estudio previo exitoso que mostró una reducción significativa en la eliminación viral y un retraso en la transmisión de la enfermedad en las aves tratadas.
El nuevo estudio tiene como objetivo optimizar formulaciones y protocolos de tratamiento para entornos de producción avícola del mundo real. Varias empresas globales de salud animal han expresado interés en las soluciones no antibióticas de ZIVO, tras los resultados positivos de los estudios sobre la influenza aviar y la coccidiosis. El enfoque de la empresa se centra en desarrollar alternativas sostenibles y rentables a los tratamientos tradicionales utilizando sus cultivos de algas patentados.
ZIVO 바이오사이언스 (OTCQB: ZIVO)는 델라웨어 대학교와 두 번째 협력 연구를 발표하며, 자사의 조류 유래 성분을 저 병원성 조류 인플루엔자(LPAI) 바이러스와 싸우는 데 적용할 방안을 탐색하고 있습니다. 이번 발표는 치료를 받은 조류에서 바이러스의 배출량을 크게 감소시키고 질병 전파를 지연시킨 이전 성공적인 연구에 이어지며 이루어졌습니다.
새로운 연구는 실제 조류 생산 환경에 대한 제형 및 치료 프로토콜을 최적화하는 것을 목표로 합니다. 여러 글로벌 동물 건강 회사들이 조류 인플루엔자 및 코크시디오시스 연구에서 긍정적인 결과를 얻은 후 ZIVO의 비항생제 솔루션에 관심을 표명했습니다. 회사의 접근 방식은 자사의 조류 배양물을 사용하여 전통적인 치료에 대한 지속 가능한 비용 효율적인 대안을 개발하는 데 중점을 두고 있습니다.
ZIVO Bioscience (OTCQB: ZIVO) annonce une deuxième étude collaborative avec l'Université du Delaware pour explorer les applications de ses ingrédients dérivés d'algues dans la lutte contre le virus de l'Influenza Aviaire de Faible Pathogénicité (LPAI) chez les volailles. Cette annonce fait suite à leur étude précédente réussie qui a montré une réduction significative de l'excrétion virale et un retard de la transmission de la maladie chez les oiseaux traités.
La nouvelle étude vise à optimiser les formulations et les protocoles de traitement pour les environnements de production avicole réels. Plusieurs entreprises mondiales de santé animale ont exprimé leur intérêt pour les solutions non antibiotiques de ZIVO, suite aux résultats positifs des études sur l'influenza aviaire et la coccidiose. L'approche de l'entreprise se concentre sur le développement d'alternatives durables et rentables aux traitements traditionnels en utilisant leurs cultures d'algues propriétaires.
ZIVO Bioscience (OTCQB: ZIVO) gibt eine zweite gemeinsame Studie mit der University of Delaware bekannt, die die Anwendungen seiner proprietären Algenbestandteile zur Bekämpfung des Low Pathogenicity Avian Influenza (LPAI) Virus bei Geflügel untersucht. Diese Ankündigung folgt auf eine erfolgreiche frühere Studie, die eine signifikante Verringerung der Virusausbreitung und eine Verzögerung der Krankheitsübertragung bei behandelten Vögeln zeigte.
Die neue Studie zielt darauf ab, Formulierungen und Behandlungsprotokolle für reale Geflügelproduktionsumgebungen zu optimieren. Mehrere internationale Unternehmen im Bereich der Tiergesundheit haben Interesse an den nicht-antibiotischen Lösungen von ZIVO bekundet, nachdem positive Ergebnisse sowohl aus Studien zu Vogelgrippe als auch zu Kokzidiose vorgelegt wurden. Der Ansatz des Unternehmens konzentriert sich auf die Entwicklung nachhaltiger, kosteneffektiver Alternativen zu traditionellen Behandlungen mithilfe ihrer proprietären Algenkulturen.
- Previous study demonstrated significant reduction in viral shedding and delayed disease transmission
- Attracted interest from multiple global animal health companies
- Development of cost-competitive alternative to traditional treatments
- Products still in research phase without immediate commercialization timeline
- Additional studies needed before potential market entry
ZIVO’s previous study with the University of
Catalyzed by encouraging findings from completed studies in avian influenza and coccidiosis, ZIVO has attracted interest from several global animal health companies seeking innovative, non-antibiotic solutions to combat disease transmission. This interest underscores the opportunity for ZIVO’s proprietary algal-derived compounds to play a role in improving poultry health and productivity.
"The University of
“This newest study represents the next step in what we expect will be a series of studies to thoroughly evaluate the potential of ZIVO's products in various avian influenza applications. By leveraging active components from our proprietary algal cultures in new indications, we aim to develop effective, natural alternatives to traditional treatments, thereby addressing the significant challenges in animal health of cost and drug resistance,” added Mr. Payne.
About ZIVO Bioscience
ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected timeframe for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes there is a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our preclinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials; our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this news release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206639313/en/
ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com
Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com
Source: ZIVO Bioscience, Inc.
FAQ
What were the results of ZIVO's first avian influenza study with University of Delaware?
How is ZIVO approaching the treatment of avian influenza in poultry?
What is the purpose of ZIVO's second study with University of Delaware?
What market interest has ZIVO's avian influenza research generated?
